Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study

D'Haens, GR; Reinisch, W; Lee, SD; Tarabar, D; Louis, E; Klopocka, M; Klaus, J; Schreiber, S; Park, DI; Hebuterne, X; Nagy, P; Cataldi, F; Martin, SW; Nayak, S; Banerjee, A; Gorelick, KJ; Sandborn, WJ

Nagy, P (通讯作者)，Takeda Pharmaceut Int AG, Thurgauerstr 130, CH-8152 Glattpark Opfikon, Switzerland.

INFLAMMATORY BOWEL DISEASES, 2022; 28 (7): 1034

Abstract

Background Patients with Crohn's disease (CD) experience intestinal inflammation. Ontamalimab (SHP647), a fully human immunoglobulin G(2) monoclonal a......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索